• +1-646-491-9876
    • +91-20-67278686

    Search

    Hospital Acquired Pneumonia Pipeline Review H2 2017

    Hospital Acquired Pneumonia Pipeline Review H2 2017

    • Report Code ID: RW0001884131
    • Category Pharmaceuticals
    • No. of Pages 161
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

    Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
    The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
    The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively.

    Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Hospital Acquired Pneumonia (HAP) - Overview 7
    Hospital Acquired Pneumonia (HAP) - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Products under Development by Companies 12
    Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 16
    Assessment by Target 16
    Assessment by Mechanism of Action 18
    Assessment by Route of Administration 20
    Assessment by Molecule Type 22
    Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 24
    Achaogen Inc 24
    Adenium Biotech ApS 24
    Aridis Pharmaceuticals LLC 25
    AstraZeneca Plc 25
    Bayer AG 26
    Cardeas Pharma Corp 26
    Destiny Pharma Ltd 27
    Dong-A Socio Holdings Co Ltd 27
    Lakewood-Amedex Inc 28
    MedImmune LLC 28
    Meiji Seika Pharma Co Ltd 29
    Melinta Therapeutics Inc 29
    Merck & Co Inc 30
    Motif Bio Plc 30
    Nabriva Therapeutics AG 31
    Polyphor Ltd 31
    Sealife PHARMA GMBH 32
    Shionogi & Co Ltd 32
    Tetraphase Pharmaceuticals Inc 33
    The Medicines Company 33
    Theravance Biopharma Inc 34
    Wockhardt Ltd 34
    Zavante Therapeutics Inc 35
    Hospital Acquired Pneumonia (HAP) - Drug Profiles 36
    (amikacin sulfate + fosfomycin) - Drug Profile 36
    (avibactam + ceftazidime) - Drug Profile 38
    (avibactam sodium + aztreonam lysine) - Drug Profile 43
    (cefepime + zidebactam) - Drug Profile 45
    (ceftolozane sulfate + tazobactam sodium) - Drug Profile 46
    (cilastatin sodium + imipenem + relebactam) - Drug Profile 51
    (meropenem+ vaborbactam) - Drug Profile 53
    AA-139 - Drug Profile 57
    Aerucin - Drug Profile 58
    alalevonadifloxacin - Drug Profile 60
    amikacin sulfate - Drug Profile 61
    arbekacin - Drug Profile 63
    ASN-100 - Drug Profile 64
    cefiderocol - Drug Profile 67
    delafloxacin meglumine - Drug Profile 71
    EBX-004 - Drug Profile 80
    eravacycline - Drug Profile 81
    exeporfinium chloride - Drug Profile 88
    fosfomycin tromethamine - Drug Profile 90
    iclaprim mesylate - Drug Profile 93
    lefamulin acetate - Drug Profile 98
    levonadifloxacin - Drug Profile 103
    MEDI-3902 - Drug Profile 104
    Mul-1867 - Drug Profile 105
    murepavadin - Drug Profile 107
    Nu-2 - Drug Profile 109
    Nu-3 - Drug Profile 110
    Panaecin - Drug Profile 112
    panobacumab - Drug Profile 113
    plazomicin sulfate - Drug Profile 115
    POL-7001 - Drug Profile 123
    Qn-2251 - Drug Profile 124
    SLP-0905 - Drug Profile 125
    sodium hypochlorite - Drug Profile 126
    suvratoxumab - Drug Profile 127
    tedizolid phosphate - Drug Profile 128
    telavancin hydrochloride - Drug Profile 136
    tosatoxumab - Drug Profile 141
    Viritron VDX - Drug Profile 143
    Hospital Acquired Pneumonia (HAP) - Dormant Projects 144
    Hospital Acquired Pneumonia (HAP) - Discontinued Products 145
    Hospital Acquired Pneumonia (HAP) - Product Development Milestones 146
    Featured News & Press Releases 146
    Appendix 157
    Methodology 157
    Coverage 157
    Secondary Research 157
    Primary Research 157
    Expert Panel Validation 157
    Contact Us 157
    Disclaimer 158

    List of Tables

    Number of Products under Development for Hospital Acquired Pneumonia (HAP) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
    Products under Development by Companies, H2 2017 (Contd..3) , H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2017
    Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2017
    Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Hospital Acquired Pneumonia (HAP) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Achaogen Inc
    Adenium Biotech ApS
    Aridis Pharmaceuticals LLC
    AstraZeneca Plc
    Bayer AG
    Cardeas Pharma Corp
    Destiny Pharma Ltd
    Dong-A Socio Holdings Co Ltd
    Lakewood-Amedex Inc
    MedImmune LLC
    Meiji Seika Pharma Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Motif Bio Plc
    Nabriva Therapeutics AG
    Polyphor Ltd
    Sealife PHARMA GMBH
    Shionogi & Co Ltd
    Tetraphase Pharmaceuticals Inc
    The Medicines Company
    Theravance Biopharma Inc
    Wockhardt Ltd
    Zavante Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments